IQ-AI Advances GaM to Phase II Study, Highlights AI Capabilities.

IQ-AI plans to take GaM to a phase II study based on encouraging preliminary signals of clinical response to GaM in a phase 1 trial for relapsed glioblastoma patients. The company also notes that its subsidiary, Imaging Biometrics LLC, is poised to lead the transformation in neuro-oncology with AI capabilities, including the release of a new version of IB Clinic with an AI model for improved diagnostic accuracy and speed.

The biotech industry is witnessing a surge of interest in the potential of artificial intelligence (AI) and machine learning (ML) to revolutionize healthcare diagnostics and treatments. One such company at the forefront of this movement is IQ-AI Ltd (LSE: IQAI), which recently reported encouraging preliminary results from its Phase 1 clinical trial of oral gallium maltolate (GaM) for relapsed glioblastoma patients [1].

In April 2021, IQ-AI initiated a Phase 1 clinical trial at the MCW Cancer Center (MCWCC) after reviewing promising pre-clinical research from the Medical College of Wisconsin (MCW) [1]. The trial, which is nearing completion, is designed to evaluate the safety, tolerability, and efficacy of GaM in treating relapsed glioblastoma patients.

The trial has demonstrated remarkable progress, with some patients remaining on treatment for over six months without disease progression [1]. This is particularly noteworthy in a cancer where patients typically experience progression within one to six months following relapse [1]. Moreover, all patients treated with GaM have tolerated the drug well, with no dose-limiting adverse side-effects reported [1].

The success of the Phase 1 trial has generated significant interest in GaM, with the clinical team, led by Dr. Jennifer Connelly (Neuro-Oncology) and Dr. Christopher Chitambar (Hematology and Medical Oncology), receiving numerous requests for presentations and lectures globally [1].

Based on the positive results from the Phase 1 trial, IQ-AI plans to proceed with a Phase 2 clinical trial to establish the recommended dose for GaM and further evaluate its safety and efficacy [1]. The company's subsidiary, Imaging Biometrics LLC, is also poised to lead the transformation in neuro-oncology with AI capabilities [1].

Imaging Biometics recently announced the release of a new version of IB Clinic, an AI-powered diagnostic tool for improved diagnostic accuracy and speed [1]. This innovative solution will undoubtedly contribute to the early detection and treatment of glioblastoma, further enhancing the potential impact of IQ-AI's work in the field.

In conclusion, IQ-AI's Phase 1 trial of GaM for relapsed glioblastoma has shown promising results, with some patients experiencing no disease progression for over six months. Based on these findings, IQ-AI plans to proceed with a Phase 2 clinical trial and continues to innovate in the field of neuro-oncology with its subsidiary, Imaging Biometics.

References:
[1] IQ-AI Ltd. (2024, June 14). RNS 4807S - 14 June 2024. Retrieved from https://www.iqai.ltd/2024/06/rns-4807s-14-june-2024/